New report of IHE in collaboration with OECD

It builds on IHE’s leading expertise in the area of access to cancer medicines. The paper examines various aspects of inequalities in access to cancer medicines, covering key stages in a medicine’s life cycle, from marketing authorization to reimbursement decisions and uptake in clinical practice. It also explores potential strategies to stimulate competition among oncology medicine producers.